Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Paul Bird, Francisco J. Blanco et al.|Annals of the Rheumatic Diseases|2016Cited by 286
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studiesDafna D. Gladman, Philip J. Mease, Christopher J Edwards et al.|RMD Open|2018Cited by 38
212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin InvolvementChristopher J Edwards, C. Birbara, Francisco J. Blanco et al.|Lara D. Veeken|2014Cited by 29
SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled TrialsPhilip J. Mease, C. Birbara, Arthur Kavanaugh et al.|Annals of the Rheumatic Diseases|2014Cited by 17
164 Long-term (four year) 28-joint count disease activity score (C-reactive protein) remission and improvements in skin disease with apremilast: phase III results from PALACE3Christopher J Edwards, C. Birbara, Francisco J. Blanco et al.|Lara D. Veeken|2018Cited by 0